1.Combination of AAV-delivered tumor suppressor PTEN with anti-PD-1 loaded depot gel for enhanced antitumor immunity.
Yongshun ZHANG ; Lan YANG ; Yangsen OU ; Rui HU ; Guangsheng DU ; Shuang LUO ; Fuhua WU ; Hairui WANG ; Zhiqiang XIE ; Yu ZHANG ; Chunting HE ; Cheng MA ; Tao GONG ; Ling ZHANG ; Zhirong ZHANG ; Xun SUN
Acta Pharmaceutica Sinica B 2024;14(1):350-364
Recent clinical studies have shown that mutation of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) gene in cancer cells may be associated with immunosuppressive tumor microenvironment (TME) and poor response to immune checkpoint blockade (ICB) therapy. Therefore, efficiently restoring PTEN gene expression in cancer cells is critical to improving the responding rate to ICB therapy. Here, we screened an adeno-associated virus (AAV) capsid for efficient PTEN gene delivery into B16F10 tumor cells. We demonstrated that intratumorally injected AAV6-PTEN successfully restored the tumor cell PTEN gene expression and effectively inhibited tumor progression by inducing tumor cell immunogenic cell death (ICD) and increasing immune cell infiltration. Moreover, we developed an anti-PD-1 loaded phospholipid-based phase separation gel (PPSG), which formed an in situ depot and sustainably release anti-PD-1 drugs within 42 days in vivo. In order to effectively inhibit the recurrence of melanoma, we further applied a triple therapy based on AAV6-PTEN, PPSG@anti-PD-1 and CpG, and showed that this triple therapy strategy enhanced the synergistic antitumor immune effect and also induced robust immune memory, which completely rejected tumor recurrence. We anticipate that this triple therapy could be used as a new tumor combination therapy with stronger immune activation capacity and tumor inhibition efficacy.
2.Mycoplasma genitalium infection of patients attending sexually transmitted disease clinic in Guangzhou
Lei XU ; Yinyuan LAN ; Qian WU ; Jinmei HUANG ; Zhengqiang HE ; Mingheng FANG ; Jiangli OU ; Xingzhong WU ; Yaohua XUE ; Bin YANG
The Journal of Practical Medicine 2024;40(10):1434-1439
Objective To assess the prevalence of mycoplasma genitalium(MG)in patients attending sexually transmitted disease(STD)clinic in Guangzhou,and to provide an epidemiological foundation for clinical treatment and laboratory diagnostics.Methods Utilizing real-time polymerase chain reaction(PCR),we analyzed MG DNA in 2,749 clinical specimens collected from 2,722 outpatients in the Dermatology Hospital of Southern Medical University from July 2019 to December 2021.Concurrent testing for MG,Chlamydia trachomatis(CT),and Neisseria gonorrhoeae(NG)was performed on 2,382 of these specimens.Patient data extracted from medical records were used to investigate the correlation between STD symptoms and MG infection.Results The investigation revealed that the overall prevalence of MG infection was 4.4%among the sampled patients(120 out of 2,722),with a higher prevalence in males(4.9%,or 87 out of 1,790)compared to in females(3.5%,or 33 out of 932).Notably,the prevalence decreased with increasing age.The highest incidence of MG infection was observed in females aged 18~25 years(6.4%,or 18 out of 281),while the lowest was in males aged 46 years and above(1.5%,or 5 out of 342),showing a statistically significant variation across age groups(P<0.05).Among males with urethritis symptoms,MG positive rate was significantly higher at 7.3%(42 out of 574).The rate of single MG infection was prominent,accounting for 89.9%(71 out of 79)in MG-positive male patients and 61.5%(16 out of 26)in MG-positive female patients.Co-infection rate of MG with CT was 1.2%in females and 0.3%in males,indicating a significant dif-ference(P<0.05).Conclusion The findings suggest a relatively high prevalence of MG infection and co-infection with CT among STD clinic attendees in Guangzhou,particularly in the younger demographic.The study underscores the need for early screening and vigilant surveillance of MG to mitigate its transmission among sexually active popula-tions at high risk.
3.Mental Health Status and Influencing Factors of Pediatricians in Guangzhou
Yan-ling LAN ; Ru-hao XIANG ; Zong-xuan FENG ; Xin-yi ZHANG ; Yi-hui WANG ; Ou-dong XIA
Journal of Sun Yat-sen University(Medical Sciences) 2023;44(1):138-144
ObjectiveTo investigate the mental health of pediatricians in Guangzhou and its influencing factors, and to provide countermeasures for improving the mental health of pediatricians. MethodsA stratified random sampling method was used to randomly select 400 pediatricians in 11 districts of Guangzhou, and they were surveyed using the Symptom Check List(SCL-90) and the Job Stressor Scale. ResultsThe top three job stressors scored by pediatricians in Guangzhou were external environment (3.23±0.59), workload (3.19±0.56), and organizational management (2.74±0.55). All factor scores were higher than those of the clinician group except for career interest, and the difference was statistically significant (P<0.01). The number of pediatricians with mental health problems was 109, accounting for 27.25%. All factor scores were higher than the physician norm except for anxiety and paranoia. The correlations between each factor of work stressors and each factor of SCL-90 were positive and statistically significant (P<0.05), except for two pairs of factors, workload and terror as well as external environment and terror. The results of univariate analysis showed statistically significant differences in the mental health scores of pediatricians with different health status, years of work experience, job satisfaction, job stress, and career prospects (P<0.05). The results of multiple linear regression showed that health status, years of work experience, professional interest, interpersonal relationship, and doctor-patient relationship were influential factors in the mental health of pediatricians (P<0.05). ConclusionThe mental health of pediatricians in Guangzhou is unsatisfactory, and the factors affecting them are mainly external objective factors such as workload and organizational management.
4.Effects of ppk1 deletion on the drug susceptibility of uropathogenic Escherichia coli producing ESBLs.
Jing Yi OU ; Wan Shan CHEN ; Mei Jun CHEN ; Ling Zhai ZHAO ; Ling Hua LI ; Liang PENG ; Lan LIANG ; Ya Ling SHI
Chinese Journal of Preventive Medicine 2023;57(8):1238-1245
To investigate the effect and the mechanism of ppk1 gene deletion on the drug susceptibility of uropathogenic Escherichia coli producing extended-spectrum beta-lactamases (ESBLs-UPEC). The study was an experimental study. From March to April 2021, a strain of ESBLs-UPEC (genotype was TEM combined with CTX-M-14) named as UE210113, was isolated from urine sample of the patient with urinary tract infection in the Laboratory Department of Guangzhou Eighth People's Hospital, meanwhile its ppk1 gene knock-out strain Δpk1 and complemented strain Δpk1-C were constructed by suicide plasmid homologous recombination technique, which was used to study the effect of ppk1 gene on ESBLs-UPEC drug sensitivity and its mechanism. The drug susceptibility of UE210113, Δpk1, and Δpk1-C were measured by Vitek2 Compact System and broth microdilution method. The quantitative expression of ESBLs, outer membrane protein and multidrug efflux systems encoding genes of UE210113, Δpk1 and Δpk1-C were performed by using qRT-PCR analysis. By using two independent sample Mann-Whitney U test, the drug susceptibility results showed that, compared with UE210113 strain, the sensitivities of Δpk1 to ceftazidime, cefepime, tobramycin, minocycline and cotrimoxazole were enhanced (Z=-2.121,P<0.05;Z=-2.236,P<0.05;Z=-2.236,P<0.05;Z=-2.121,P<0.05), and the drug susceptibility of Δpk1-C restored to the same as which of UE210113 (Z=0,P>0.05). The expression levels of ESBLs-enconding genes blaTEM and blaCTX-M-14 in Δpk1 were significantly down-regulated compared with UE210113, but the expression was not restored in Δpk1-C. The expression of outer membrane protein gene omp F in Δpk1 was significantly up-regulated, while the expression of omp A and omp C were down-regulated. The results showed that the expression of multidrug efflux systems encoding genes tol C, mdt A and mdtG were down-regulated in Δpk1 compared with UE210113. The expression of all of the outer membrane protein genes and the multidrug efflux systems genes were restored in Δpk1-C. In conclusion,the lost of ppk1 gene can affect the expression of the outer membrane protein and multidrug efflux systems encoding genes of ESBLs-UPEC, which increase the sensitivity of ESBLs-UPEC to various drugs.
Humans
;
beta-Lactamases/metabolism*
;
Uropathogenic Escherichia coli/metabolism*
;
Urinary Tract Infections
;
Plasmids
;
Membrane Proteins/genetics*
;
Escherichia coli Infections
;
Microbial Sensitivity Tests
;
Anti-Bacterial Agents/pharmacology*
5.Effects of ppk1 deletion on the drug susceptibility of uropathogenic Escherichia coli producing ESBLs.
Jing Yi OU ; Wan Shan CHEN ; Mei Jun CHEN ; Ling Zhai ZHAO ; Ling Hua LI ; Liang PENG ; Lan LIANG ; Ya Ling SHI
Chinese Journal of Preventive Medicine 2023;57(8):1238-1245
To investigate the effect and the mechanism of ppk1 gene deletion on the drug susceptibility of uropathogenic Escherichia coli producing extended-spectrum beta-lactamases (ESBLs-UPEC). The study was an experimental study. From March to April 2021, a strain of ESBLs-UPEC (genotype was TEM combined with CTX-M-14) named as UE210113, was isolated from urine sample of the patient with urinary tract infection in the Laboratory Department of Guangzhou Eighth People's Hospital, meanwhile its ppk1 gene knock-out strain Δpk1 and complemented strain Δpk1-C were constructed by suicide plasmid homologous recombination technique, which was used to study the effect of ppk1 gene on ESBLs-UPEC drug sensitivity and its mechanism. The drug susceptibility of UE210113, Δpk1, and Δpk1-C were measured by Vitek2 Compact System and broth microdilution method. The quantitative expression of ESBLs, outer membrane protein and multidrug efflux systems encoding genes of UE210113, Δpk1 and Δpk1-C were performed by using qRT-PCR analysis. By using two independent sample Mann-Whitney U test, the drug susceptibility results showed that, compared with UE210113 strain, the sensitivities of Δpk1 to ceftazidime, cefepime, tobramycin, minocycline and cotrimoxazole were enhanced (Z=-2.121,P<0.05;Z=-2.236,P<0.05;Z=-2.236,P<0.05;Z=-2.121,P<0.05), and the drug susceptibility of Δpk1-C restored to the same as which of UE210113 (Z=0,P>0.05). The expression levels of ESBLs-enconding genes blaTEM and blaCTX-M-14 in Δpk1 were significantly down-regulated compared with UE210113, but the expression was not restored in Δpk1-C. The expression of outer membrane protein gene omp F in Δpk1 was significantly up-regulated, while the expression of omp A and omp C were down-regulated. The results showed that the expression of multidrug efflux systems encoding genes tol C, mdt A and mdtG were down-regulated in Δpk1 compared with UE210113. The expression of all of the outer membrane protein genes and the multidrug efflux systems genes were restored in Δpk1-C. In conclusion,the lost of ppk1 gene can affect the expression of the outer membrane protein and multidrug efflux systems encoding genes of ESBLs-UPEC, which increase the sensitivity of ESBLs-UPEC to various drugs.
Humans
;
beta-Lactamases/metabolism*
;
Uropathogenic Escherichia coli/metabolism*
;
Urinary Tract Infections
;
Plasmids
;
Membrane Proteins/genetics*
;
Escherichia coli Infections
;
Microbial Sensitivity Tests
;
Anti-Bacterial Agents/pharmacology*
6.Patient-Reported Outcomes of PD-1 Inhibitor Camrelizumab Combined with Antiangiogenic Drug Apatinib in Patients with Advanced Cervical Cancer
Yue-rong LAI ; Yue JIANG ; Xin HUANG ; Yu-lan OU
Journal of Sun Yat-sen University(Medical Sciences) 2022;43(4):591-599
ObjectiveA previous multicenter, single-arm phase Ⅱ clinical study evaluated the efficacy and safety of the PD-1 inhibitor camrelizumab in combination with the antiangiogenic drug apatinib in patients with recurrent/metastatic cervical cancer. In the current study, we aimed to report the patient-reported outcomes (PRO) in patients with advanced cervical cancer. MethodsThe researchers filled out quality of life questionnaire FACT-Cx with the patients face-to-face at the baseline and every two treatment cycles. The patients provided the questionnaire until disease progression. For patients who continued the study, the data cutoff date for the questionnaire was Oct12, 2020. ResultsIn this study, 41 patients who received treatment finished at least one FACT-Cx questionnaire. The scores of FACT-Cx questionnaire at baseline, the first 6 cycles, and after 6 cycles of treatment (range, 7-15cycle) were 114.53±18.23, 124.08±15.23 and 132.82±21.97, respectively. The scores of questionnaire at the first 6 cycle and after 6 cycles of treatment were significantly increased when compared with those at baseline (P<0.05). With respect to each dimension of the FACT-Cx questionnaire, physical status (such as mental state, limb pain), emotional status (such as sadness, tension), functional status (such as daily activities) and additional concerns (such as sexual function), the average scores of these dimensions was significantly higher after 6 treatment cycles than those at baseline (P<0.05). Social/family status dimensions (such as family relationships) did not change significantly. In the first 6 cycles, the incidence of grade 3 to 4 adverse events (AEs) was 71.11%. However, the incidence of grade 3 to 4 AEs decreased significantly to 25.0% after 6 treatment cycles, with the frequencies of hypertension and fatigue decreasing significantly. ConclusionsCamrelizumab combined with apatinib significantly improves the overall quality of life of patients with recurrent/metastatic cervical cancer. The scores of FACT-Cx questionnaire in multiple dimensions, such as physiological status, emotional status, functional status, and the additional status were significantly increased. Moreover, the questionnaire scores still increase after 6 treatment cycles compared with those of the first 6 cycles, indicating that the improvement of quality of life is durable.
7.Toxic epidermal necrosis in a child.
Xiao Ou LAN ; Tian SUN ; Heng Fang XIANG ; Qiang WANG ; Xiao Dong SUN ; Xian Wei HAN
Chinese Journal of Pediatrics 2022;60(9):951-952
8.An elevated platelet-to-lymphocyte ratio is associated with a higher risk of intracranial atherosclerotic stenosis
Yanhua HUANG ; Zuoteng WANG ; Bing ZHAO ; Yahui MA ; Yanan OU ; Hao HU ; Xiaohe HOU ; Jintai YU ; Lan TAN
Chinese Medical Journal 2022;135(12):1425-1431
Background::Previous studies have shown that inflammation plays an important role in intracranial atherosclerotic stenosis (ICAS). The platelet-to-lymphocyte ratio (PLR) has recently emerged as a potential inflammatory biomarker. This study aimed to explore the association of the PLR with ICAS in a Chinese Han population.Methods::A total of 2134 participants (518 with ICAS, 1616 without ICAS) were enrolled in this study. ICAS was defined as atherosclerotic stenosis >50% or the occlusion of several main intracranial arteries. Multivariable logistic regression analyses were used to assess the association of the PLR with ICAS. Additional subgroup analyses were performed according to age (<60 vs. ≥ 60 years) and acute ischemic stroke. Results::Multivariate regression analysis showed that a high PLR was associated with a higher risk of ICAS in all participants ( P < 0.001). Compared with the lowest quartile, the fourth PLR quartile was significantly associated with ICAS (OR 1.705, 95% confidence interval 1.278–2.275, P < 0.001). In the subgroups stratified by age, an association between the PLR and ICAS was found in the late-life group ( P < 0.001), but not in the mid-life group ( P = 0.650). In the subgroups stratified by acute ischemic stroke, the relationship between an elevated PLR and a higher risk of ICAS remained unchanged (stroke group, P < 0.001; non-stroke group, P = 0.027). Conclusions::An elevated PLR was associated with a higher risk of ICAS in a Chinese Han population. The PLR might serve as a potential biomarker for ICAS in the elderly population.
10.Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group
Chyong Huey LAI ; Elizabeth VALLIKAD ; Hao LIN ; Lan Yan YANG ; Shih Ming JUNG ; Hsueh Erh LIU ; Yu Che OU ; Hung Hsueh CHOU ; Cheng Tao LIN ; Huei Jean HUANG ; Kuan Gen HUANG ; Jiantai QIU ; Yao Ching HUNG ; Tzu I WU ; Wei Yang CHANG ; Kien Thiam TAN ; Chiao Yun LIN ; Angel CHAO ; Chee Jen CHANG
Journal of Gynecologic Oncology 2020;31(1):5-

Result Analysis
Print
Save
E-mail